Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
NASDAQ:FGEN
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.03Last Year’s EPS
-0.33Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 17, 2025
|% Change Since: -22.73%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant strategic steps such as the sale of FibroGen China, which strengthens the financial position and supports key pipeline advancements in oncology. However, challenges remain with revenue declines and net losses.Company Guidance
During the FibroGen Fourth Quarter and Full Year 2024 Earnings Conference Call, guidance was provided on several key metrics and strategic initiatives. FibroGen announced the sale of FibroGen China to AstraZeneca for approximately $160 million, extending their cash runway into 2027 and simplifying operations. The company plans to focus on U.S. pipeline opportunities, particularly FG-3246 and FG-3180, in metastatic castration-resistant prostate cancer (mCRPC). Notably, FG-3246 showed promising results in Phase 1 trials with an 8.7-month median radiographic progression-free survival and a 20% overall response rate. Financially, FibroGen reported a 51% year-over-year decrease in total operating costs and a 43% decrease in SG&A expenses, contributing to a net loss reduction from $323 million in 2023 to $153.1 million in 2024. Looking ahead, the company anticipates $4 million to $8 million in total revenue for 2025 and plans to initiate several clinical trials, including a Phase 2 dose optimization study for FG-3246 by mid-2025.Sale of FibroGen China
The sale of FibroGen China to AstraZeneca for approximately $160 million is a transformative transaction that simplifies operations, allows for debt repayment, and extends the cash runway into 2027.
FG-3246 and FG-3180 Advancements
Progress in the development of FG-3246 for metastatic castration-resistant prostate cancer with promising Phase 1 data showing a median radiographic progression-free survival of 8.7 months and an overall response rate of 20%.
Cost Reduction and Financial Improvement
Significant reduction in operating expenses by 51% year-over-year and a decrease in net loss from continuing operations by 53% compared to the previous year, along with a strong cash position.
Roxadustat Opportunity
Potential to develop roxadustat for anemia associated with lower-risk MDS, with a planned FDA meeting to explore this opportunity.
---
FGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
FGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 17, 2025 | $0.44 | $0.35 | -20.45% |
| Nov 12, 2024 | $0.39 | $0.33 | -15.38% |
| Aug 06, 2024 | $0.44 | $0.46 | +4.55% |
| May 06, 2024 | $1.16 | $1.37 | +18.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does FibroGen (FGEN) report earnings?
FibroGen (FGEN) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is FibroGen (FGEN) earnings time?
FibroGen (FGEN) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FGEN EPS forecast?
FGEN EPS forecast for the fiscal quarter 2025 (Q1) is 0.03.
---